Aradigm Co. (ARDM) Insider Sells $26,026.83 in Stock

Aradigm Co. (NASDAQ:ARDM) insider Juergen Kurt Froehlich sold 17,011 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $1.53, for a total value of $26,026.83. Following the completion of the sale, the insider now owns 90,853 shares in the company, valued at approximately $139,005.09. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Aradigm Co. (ARDM) opened at $1.29 on Friday. The company has a debt-to-equity ratio of -1.59, a quick ratio of 1.65 and a current ratio of 1.65. Aradigm Co. has a 52 week low of $0.78 and a 52 week high of $7.35. The company has a market capitalization of $20.18, a price-to-earnings ratio of -1.31 and a beta of 0.81.

Aradigm (NASDAQ:ARDM) last issued its earnings results on Thursday, November 2nd. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05. The business had revenue of $2.73 million for the quarter. equities research analysts anticipate that Aradigm Co. will post -0.8 earnings per share for the current year.

An institutional investor recently bought a new position in Aradigm stock. Jane Street Group LLC bought a new stake in shares of Aradigm Co. (NASDAQ:ARDM) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 29,025 shares of the company’s stock, valued at approximately $122,000. Jane Street Group LLC owned about 0.19% of Aradigm at the end of the most recent quarter. 32.02% of the stock is currently owned by institutional investors.

Several research firms recently weighed in on ARDM. Zacks Investment Research downgraded Aradigm from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Ladenburg Thalmann Financial Services downgraded Aradigm from a “buy” rating to a “neutral” rating in a research note on Friday, January 12th. Finally, ValuEngine upgraded Aradigm from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th.

TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at

Aradigm Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with's FREE daily email newsletter.

Leave a Reply